Cargando…
Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
In the phase III PALETTE trial, pazopanib improved progression-free survival (PFS) compared with placebo in patients with advanced/metastatic soft tissue sarcomas (mSTS) who had received prior chemotherapy. We used a multistate model to estimate expected PFS, overall survival (OS), lifetime STS trea...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082932/ https://www.ncbi.nlm.nih.gov/pubmed/25024640 http://dx.doi.org/10.1155/2014/481071 |
_version_ | 1782324314164428800 |
---|---|
author | Amdahl, Jordan Manson, Stephanie C. Isbell, Robert Chit, Ayman Diaz, Jose Lewis, Lily Delea, Thomas E. |
author_facet | Amdahl, Jordan Manson, Stephanie C. Isbell, Robert Chit, Ayman Diaz, Jose Lewis, Lily Delea, Thomas E. |
author_sort | Amdahl, Jordan |
collection | PubMed |
description | In the phase III PALETTE trial, pazopanib improved progression-free survival (PFS) compared with placebo in patients with advanced/metastatic soft tissue sarcomas (mSTS) who had received prior chemotherapy. We used a multistate model to estimate expected PFS, overall survival (OS), lifetime STS treatment costs, and quality-adjusted life-years (QALYs) for patients receiving pazopanib, placebo, trabectedin, ifosfamide, or gemcitabine plus docetaxel as second-line mSTS therapies. The cost-effectiveness of pazopanib was expressed as the incremental costs per QALY gained. Estimates of PFS/OS, adverse events, and utilities for pazopanib and placebo were from the PALETTE trial. Estimates of relative effectiveness of the other comparators were from an unadjusted indirect comparison versus pazopanib. Costs were from published sources. Pazopanib is estimated to increase QALYs by 0.128 and costs by £7,976 versus placebo; cost per QALY gained with pazopanib versus placebo is estimated to be £62,000. Compared with the other chemotherapies, pazopanib provides similar QALYs at a lower cost. Pazopanib may not be cost-effective versus placebo but may be cost-effective versus the most commonly used active treatments, although this conclusion is uncertain. Given the unmet need for effective treatments for mSTS, pazopanib may be an appropriate alternative to some currently used medications in the United Kingdom. |
format | Online Article Text |
id | pubmed-4082932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40829322014-07-14 Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom Amdahl, Jordan Manson, Stephanie C. Isbell, Robert Chit, Ayman Diaz, Jose Lewis, Lily Delea, Thomas E. Sarcoma Research Article In the phase III PALETTE trial, pazopanib improved progression-free survival (PFS) compared with placebo in patients with advanced/metastatic soft tissue sarcomas (mSTS) who had received prior chemotherapy. We used a multistate model to estimate expected PFS, overall survival (OS), lifetime STS treatment costs, and quality-adjusted life-years (QALYs) for patients receiving pazopanib, placebo, trabectedin, ifosfamide, or gemcitabine plus docetaxel as second-line mSTS therapies. The cost-effectiveness of pazopanib was expressed as the incremental costs per QALY gained. Estimates of PFS/OS, adverse events, and utilities for pazopanib and placebo were from the PALETTE trial. Estimates of relative effectiveness of the other comparators were from an unadjusted indirect comparison versus pazopanib. Costs were from published sources. Pazopanib is estimated to increase QALYs by 0.128 and costs by £7,976 versus placebo; cost per QALY gained with pazopanib versus placebo is estimated to be £62,000. Compared with the other chemotherapies, pazopanib provides similar QALYs at a lower cost. Pazopanib may not be cost-effective versus placebo but may be cost-effective versus the most commonly used active treatments, although this conclusion is uncertain. Given the unmet need for effective treatments for mSTS, pazopanib may be an appropriate alternative to some currently used medications in the United Kingdom. Hindawi Publishing Corporation 2014 2014-06-12 /pmc/articles/PMC4082932/ /pubmed/25024640 http://dx.doi.org/10.1155/2014/481071 Text en Copyright © 2014 Jordan Amdahl et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Amdahl, Jordan Manson, Stephanie C. Isbell, Robert Chit, Ayman Diaz, Jose Lewis, Lily Delea, Thomas E. Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom |
title | Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom |
title_full | Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom |
title_fullStr | Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom |
title_full_unstemmed | Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom |
title_short | Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom |
title_sort | cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the united kingdom |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082932/ https://www.ncbi.nlm.nih.gov/pubmed/25024640 http://dx.doi.org/10.1155/2014/481071 |
work_keys_str_mv | AT amdahljordan costeffectivenessofpazopanibinadvancedsofttissuesarcomaintheunitedkingdom AT mansonstephaniec costeffectivenessofpazopanibinadvancedsofttissuesarcomaintheunitedkingdom AT isbellrobert costeffectivenessofpazopanibinadvancedsofttissuesarcomaintheunitedkingdom AT chitayman costeffectivenessofpazopanibinadvancedsofttissuesarcomaintheunitedkingdom AT diazjose costeffectivenessofpazopanibinadvancedsofttissuesarcomaintheunitedkingdom AT lewislily costeffectivenessofpazopanibinadvancedsofttissuesarcomaintheunitedkingdom AT deleathomase costeffectivenessofpazopanibinadvancedsofttissuesarcomaintheunitedkingdom |